Search form
Search
contact us
Navigation
home
boards
Jobs
job ratings
cp wire
medtech news
pharmagather
catering
advertise
whistleblower info
pharmaceutical fraud
medical device | DME fraud
clinical lab fraud
False Claims Act
Legal Help
login/register
You are here
Home
»
companies
» Padcev
Padcev
Padcev, Keytruda, and Balversa leave little room for Opdivo in urothelial carcinoma
Clinical Trials Arena
Thu, 03/21/24 - 06:41 pm
bladder cancer
urothelial cancer
Merck
Pfizer
Bristol Myers Squibb
Padcev
Keytruda
Balversa
Opdivo
Astellas' sales expectations are up for Padcev, down for Veozah
Fierce Pharma
Mon, 02/5/24 - 11:02 pm
Astellas
earnings
Padcev
Merck, Astellas and Pfizer bring down the house with Keytruda-Padcev FDA nod in bladder cancer
Fierce Pharma
Tue, 12/19/23 - 10:26 am
Merck
Astellas
Pfizer
Keytruda
Padcev
bladder cancer
FDA starts review of Padcev/Keytruda for bladder cancer
Pharmaphorum
Fri, 12/1/23 - 09:35 am
Merck
Astellas
Seagen
Padcev
bladder cancer
FDA
priority review
Merck, BMS Score Separate Late-Stage Victories in Bladder Cancer at ESMO
BioSpace
Mon, 10/23/23 - 05:15 pm
ESMO
Merck
Bristol Myers Squibb
bladder cancer
PD-1 inhibitors
Keytruda
Padcev
Opdivo
ESMO: Bristol Myers' Opdivo chalks up bladder cancer win. But a rival combo casts long shadow
Fierce Pharma
Sun, 10/22/23 - 06:06 pm
ESMO
Bristol Myers Squibb
Opdivo
bladder cancer
Padcev
Keytruda
Merck
ESMO: Seagen, Astellas and Merck knock it out of the park with Padcev-Keytruda combo in bladder cancer
Fierce Pharma
Wed, 10/18/23 - 11:42 am
Seagen
Astellas
Merck
Padcev
Keytruda
bladder cancer
ESMO
Merck, Seagen and Astellas Get Late-Stage Win in Bladder Cancer with Combo
BioSpace
Fri, 09/22/23 - 11:53 am
Merck
Seagen
Astellas
urothelial cancer
clinical trials
bladder cancer
Padcev
Keytruda
FDA Approves Keytruda/Padcev Combo in Advanced Urothelial Cancer
BioSpace
Tue, 04/4/23 - 12:35 pm
Merck
Seagen
Astellas
Keytruda
Padcev
metastatic urothelial carcinoma
FDA
ASCO-GU – Bicycle tries to put distance between itself and Seagen
EP Vantage
Thu, 02/16/23 - 10:15 am
ASCO-GU
Bicycle Therapeutics
Seagen
Padcev
urothelial cancer
BT8009
On the turnaround trail, tiny Corbus pays $7.5M for rival to Seagen's oncology ADC Padcev
Fierce Biotech
Mon, 02/13/23 - 10:29 am
Corbus Pharmaceuticals
Seagen
Padcev
CRB-701
oncology
ESMO: Seagen's Padcev pulls its weight in combo with Merck's Keytruda
Fierce Pharma
Thu, 09/8/22 - 04:40 pm
Merck
Keytruda
Astellas
Seagen
Padcev
ESMO
urothelial cancer
Seagen's (SGEN) Cancer Drugs Aid Growth, Stiff Rivalry a Woe
Yahoo/Zacks.com
Fri, 08/12/22 - 10:12 am
Seagen
Adcetris
Padcev
Tukysa
Tivdak
Merck
M&A
Seagen, Astellas claim positive results in study key to cancer drug's success
BioPharma Dive
Tue, 07/26/22 - 11:26 am
Seagen
Astellas
Padcev
Merck
Keytruda
bladder cancer
clinical trials
Trial win sets up new use for Astellas, Seagen’s Padcev in bladder cancer
Pharmaforum
Mon, 02/14/22 - 11:44 pm
Astellas
Seagen
Padcev
bladder cancer
clinical trials
FDA Approvals Roundup: Kerendia, Padcev, Darzalex Faspro
RAPS.org
Thu, 07/15/21 - 12:34 pm
FDA
drug approvals
Bayer
Kerendia
Astellas
Padcev
Teva Pharmaceutical
ArmonAir RespiClick
Janssen
Darzalex Faspro
Seagen, Astellas' Padcev snares full approval and expands into second-line treatment on path to blockbuster land
Fierce Pharma
Sat, 07/10/21 - 12:00 am
Astellas
Seagen
Padcev
FDA
bladder cancer
#ASCO21: Ahead of August PDUFA date, Astellas and Seagen sweeten Padcev pitch with new data
Endpoints
Thu, 05/20/21 - 12:16 pm
ASCO 2021
Astellas
Seagen
Padcev
FDA
urothelial cancer
Seagen gets August PDUFA for Padcev expansions
Endpoints
Mon, 04/19/21 - 10:25 pm
Seagen
FDA
Padcev
Astellas
Asco-GU – confirmatory Padcev trial throws a curveball
EP Vantage
Fri, 02/12/21 - 10:59 am
Astellas
Seagen
Padcev
bladder cancer
ASCO-GU
Pages
1
2
next ›
last »